Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.

Yuan J, Wong IL, Jiang T, Wang SW, Liu T, Wen BJ, Chow LM, Wan Sheng B.

Eur J Med Chem. 2012 Aug;54:413-22. doi: 10.1016/j.ejmech.2012.05.026. Epub 2012 Jun 4.

PMID:
22743241
2.

Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.

Li XQ, Wang L, Lei Y, Hu T, Zhang FL, Cho CH, To KK.

Eur J Med Chem. 2015 Aug 28;101:560-72. doi: 10.1016/j.ejmech.2015.06.049. Epub 2015 Jul 10.

PMID:
26197160
3.

Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.

Teodori E, Dei S, Floriddia E, Perrone MG, Manetti D, Romanelli MN, Contino M, Colabufo NA.

ChemMedChem. 2015 Aug;10(8):1339-43. doi: 10.1002/cmdc.201500143. Epub 2015 May 26.

PMID:
26012726
4.

Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.

Wong IL, Wang BC, Yuan J, Duan LX, Liu Z, Liu T, Li XM, Hu X, Zhang XY, Jiang T, Wan SB, Chow LM.

J Med Chem. 2015 Jun 11;58(11):4529-49. doi: 10.1021/acs.jmedchem.5b00085. Epub 2015 Jun 2.

PMID:
25985195
5.

Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.

Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y.

Cancer Chemother Pharmacol. 2007 Nov;60(6):789-97. Epub 2007 Mar 8.

PMID:
17345086
6.

HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).

Köhler SC, Wiese M.

J Med Chem. 2015 May 14;58(9):3910-21. doi: 10.1021/acs.jmedchem.5b00188. Epub 2015 Apr 24.

PMID:
25855895
7.

Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.

Coburger C, Wollmann J, Krug M, Baumert C, Seifert M, Molnár J, Lage H, Hilgeroth A.

Bioorg Med Chem. 2010 Jul 15;18(14):4983-90. doi: 10.1016/j.bmc.2010.06.004. Epub 2010 Jun 9.

PMID:
20598550
8.
9.

In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.

Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M, Wiese M.

Int J Cancer. 2006 Jul 15;119(2):414-22.

10.
12.

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH.

Mol Cancer Ther. 2002 Apr;1(6):417-25.

13.

Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.

Ojima I, Borella CP, Wu X, Bounaud PY, Oderda CF, Sturm M, Miller ML, Chakravarty S, Chen J, Huang Q, Pera P, Brooks TA, Baer MR, Bernacki RJ.

J Med Chem. 2005 Mar 24;48(6):2218-28.

PMID:
15771464
14.

Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

Shepard RL, Cao J, Starling JJ, Dantzig AH.

Int J Cancer. 2003 Jan 1;103(1):121-5.

15.

4,5-Di-substituted benzyl-imidazol-2-substituted amines as the structure template for the design and synthesis of reversal agents against P-gp-mediated multidrug resistance breast cancer cells.

Zhang N, Zhang Z, Wong IL, Wan S, Chow LM, Jiang T.

Eur J Med Chem. 2014 Aug 18;83:74-83. doi: 10.1016/j.ejmech.2014.06.016. Epub 2014 Jun 10.

PMID:
24952376
16.

ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.

Daood M, Tsai C, Ahdab-Barmada M, Watchko JF.

Neuropediatrics. 2008 Aug;39(4):211-8. doi: 10.1055/s-0028-1103272. Epub 2009 Jan 22.

17.

Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.

Juvale K, Pape VF, Wiese M.

Bioorg Med Chem. 2012 Jan 1;20(1):346-55. doi: 10.1016/j.bmc.2011.10.074. Epub 2011 Nov 3.

PMID:
22112540
18.

Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.

Huang XC, Sun YL, Salim AA, Chen ZS, Capon RJ.

Biochem Pharmacol. 2013 May 1;85(9):1257-68. doi: 10.1016/j.bcp.2013.02.005. Epub 2013 Feb 13.

PMID:
23415901
19.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
20.

Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines.

Cuestas ML, Sosnik A, Mathet VL.

Mol Pharm. 2011 Aug 1;8(4):1152-64. doi: 10.1021/mp2000132. Epub 2011 Jun 7.

PMID:
21591727

Supplemental Content

Support Center